Curated News
By: NewsRamp Editorial Staff
June 11, 2025
Burcon Nutrascience Scales Up Pea Protein Production, Eyes Profitability
TLDR
- Burcon Nutrascience Corporation's rapid scale-up of pea protein production and a $6.8M multi-year agreement positions it to capitalize on the growing plant-based protein market.
- Burcon Nutrascience Corporation scaled pea protein production in under 90 days at its Galesburg facility, leveraging a ProMan partnership for capital efficiency and market readiness.
- Burcon Nutrascience Corporation's advancements in plant-based proteins contribute to sustainable food solutions, enhancing global nutrition and reducing environmental impact.
- Burcon Nutrascience Corporation innovates with Peazazz® pea and Solatein™ sunflower proteins, transforming the future of food with novel plant-based alternatives.
Impact - Why it Matters
This news is significant for investors and the plant-based protein industry, showcasing Burcon Nutrascience's rapid production scale-up and strategic partnerships that pave the way for profitability. The company's innovative protein products and financial health signal strong growth potential in the burgeoning plant-based food sector.
Summary
Burcon Nutrascience Corporation (TSX: BU) has made significant strides in its strategic initiatives, notably scaling up commercial production of its pea protein isolate at its Galesburg facility in under 90 days. This rapid scale-up positions Burcon to meet growing customer demand and capitalize on revenue opportunities, including a $6.8M multi-year production agreement. The company's partnership with ProMan has been instrumental, enabling Burcon to operate a protein production facility while maintaining a capital-light stance. With production now online, Burcon anticipates first-year sales between $1M and $3M, projecting over $10M in revenue by the second year, aiming for profitability and positive cash flows by FY26.
Additionally, Burcon has expanded its product line, introducing next-generation Peazazz® pea protein and Puratein® canola protein for egg replacement applications, alongside the innovative Solatein™ sunflower protein isolate. Financially, Burcon reported $0.38M in total revenues for the year, bolstered by a successful rights offering that raised $9.4M, ensuring liquidity until achieving cash flow positivity. Stonegate Capital Partners' valuation of Burcon, using a DCF model, suggests a promising future with a valuation range of $19.36 to $24.52.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Burcon Nutrascience Scales Up Pea Protein Production, Eyes Profitability
